Pediatric Hematology Research Training Program

项目总结 儿科血液学研究培训计划的主要目标是培训个人- 主要是儿科血液学/肿瘤学研究员-在与儿科相关的良性、良性的学术或工业职业生涯中 血液学。儿科良性血液学是一个受到高度忽视的研究领域。我们的部门，由 这位T32在吸引、培训和留住年轻的有才华的人进入这个领域方面表现出色 在儿科良性血液学研究中扮演领导角色。在今次的续期中，我们建议扩大 我们的T32，将我们的博士后名额从每年4个增加到6个，以追求新的、更雄心勃勃的愿景。这个 本次更新的具体目标如下：(1)本次T32更新将提供广泛的研究培训 血红蛋白病和其他贫血、止血/儿科的特殊进口机会 血栓形成，巨核细胞/血小板生物学，输血医学，干细胞开发，骨髓衰竭， 现在，我们来看看血管生成。(2)它将支持一大批有潜力的学员。除了儿科 血液学/肿瘤学研究员库我们将包括：I.有兴趣从事的非血液学儿科研究员 良性血液学研究，以及II。建议的镰状细胞病(SCD)专科的候选人 培训计划，提供与SCD相关的最先进的研究培训。(3)培训将继续包括 由主要导师和具有关键辅助技能(如生物信息学或基因)的咨询教员组成的“团队”方法 治疗)。(4)T32基础设施将继续仔细监测个别学员的进展情况，并 通过一种新颖的“阶梯式监督”，为达到合适的下一职业里程碑提供指导 旨在将儿童血液学/肿瘤学研究员从临床年(S)过渡到他们的早期的委员会 多年来一直担任助理教授。(5)我们的计划将继续强调获得关键技能 成功的学术生涯。编写手稿、演示文稿和赠款申请，详细说明 生物伦理培训、实验室或研究人员领导技能，以及优化身份验证的专门培训 在设计实验室和/或临床研究方面，以及在严格的数据分析方面。培训教职员工 由一群富有成效的、资金充足的儿科良性血液内科医生和 作为导师的科学家具有良好的记录，并辅之以额外的培训者，这些培训者带来了 祝我们的实习生取得成功。我们的项目在少数民族学生的研究性培训中取得了成功，这 努力仍然是一个优先事项，拟议将寻求SCD专题研究金的受训人员包括在内应 进一步提升。尽管国家趋势远离儿科的子专业研究培训，但这款T32 机制使我们的计划能够培养优秀的学术生涯候选人成为国家 以及多个良性儿科血液学领域的国际领导者。我们相信，我们扩大的视野 我们的T32更新提案显示了该计划的持续活力，以及它发展和保持的能力 与我们良性儿科血液学领域的相关性。

PROJECT SUMMARY The primary objective of the Pediatric Hematology Research Training Program has been to train individuals – mostly pediatric hematology/oncology fellows – for academic or industrial careers in pediatric-related, benign hematology. Pediatric benign hematology is a highly underserved area of research. Our Division, supported by this T32, has excelled at attracting, training, and retaining young, talented individuals to this field who have risen to leadership roles in pediatric benign hematology research. In this renewal, we propose to expand the scope of our T32, increasing our slots from 4 to 6 postdoctoral slots per year to pursue a new, more ambitious vision. The Specific Aims of this renewal are as follows: (1) This T32 renewal will offer a wide range of research training opportunities of particular import to pediatrics in hemoglobinopathies and other anemias, hemostasis/ thrombosis, megakaryocyte/platelet biology, transfusion medicine, stem cell development, bone marrow failure, and now, vasculogenesis. (2) It will support a wide pool of potential trainees. Besides the pediatric hematology/oncology fellows pool we will include: i. non-hematology pediatric fellows interested in pursuing research in benign hematology, and ii. candidates from a proposed sickle cell disease (SCD) subspecialty training program offering state-of-the-art research training related to SCD. (3) Training will continue to involve a “team” approach of a primary mentor plus advisory faculty with key ancillary skills (e.g., bioinformatics or gene therapy). (4) The T32 infrastructure will continue to carefully monitor individual trainee progress and oversee mentorship towards reaching the appropriate next career milestones using a novel “stepwise oversight” committee designed to transition pediatric hematology/oncology fellows from their clinical year(s) to their early assistant professor years. (5) Our program will continue to emphasize acquisition of skills critical for successful academic careers. Preparation of manuscripts, presentations and grant submissions, detailed bioethical training, laboratory or investigator leadership skills, and specific training in optimizing authentication of key reagents, in designing the laboratory and/or clinical study, and in rigorous data analysis. Thetraining faculty is comprised of a closely-knit group of productive, well-funded, pediatric benign hematology physicians and scientists with strong records as mentors, supplemented by additional trainers that bring in skills key for the success of our trainees. Our program has been successful in the research training of minority students, and this effort remains a priority that the proposed inclusion of trainees pursuing a SCD subspecialty fellowship should further enhance. Despite a national trend away from subspecialty research training in pediatrics, this T32 mechanism has enabled our Program to train outstanding candidates for academic careers to become national and international leaders in many areas of benign pediatric hematology. We believe that the expanded vision we propose for our T32 renewal shows the program’s continued vigor, and its ability to evolve and maintain relevance in our field of benign pediatric hematology.